Janet Bryanton1, Joey Gareri2, Diane Boswall3, Mary Jean McCarthy1, Bonnie Fraser4, Donna Walsh5, Bridget Freeman5, Gideon Koren2, Kathy Bigsby4. 1. School of Nursing, University of Prince Edward Island, Charlottetown, PEI. 2. Motherisk Program, The Hospital for Sick Children, Toronto, Ont. ; Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ont. 3. PEI Reproductive Care Program, Charlottetown, PEI. 4. Queen Elizabeth Hospital, Charlottetown, PEI. 5. Prince County Hospital, Summerside, PEI.
Abstract
BACKGROUND: Fetal alcohol spectrum disorder (FASD) is a leading preventable cause of neurodevelopmental disability in North America. The stigma associated with alcohol use and abuse during pregnancy makes it difficult to obtain information on prenatal alcohol use through self-reporting. We assessed the incidence of prenatal alcohol exposure in Prince Edward Island to facilitate future public health initiatives addressing FASD. METHODS: Prenatal alcohol exposure was examined via population-based collection of meconium and analysis of fatty acid ethyl esters (FAEEs). Fatty acid ethyl esters are nonoxidative metabolites of ethanol that are produced in the fetus. Meconium FAEE concentrations of 2.0 nmol/g or greater are indicative of frequent prenatal alcohol exposure during the last 2 trimesters of pregnancy. Samples were collected from 1307 neonates between Nov. 8, 2010, and Nov. 8, 2011, in hospitals in PEI, or from those born to mothers who resided in PEI but gave birth in Halifax, Nova Scotia. Samples were frozen and shipped for analysis. Fatty acid ethyl esters were analyzed by gas chromatography-mass spectrometry and quantified by means of deuterated internal standards. RESULTS: Of the 1307 samples collected, 1271 samples were successfully analyzed. Positive results for FAEEs were obtained in 3.1% (n = 39) of samples collected within the first 24 hours after birth. INTERPRETATION: Not all neonates exposed to heavy prenatal alcohol in utero will exhibit FASD; based on current estimates of predictive value for disease by exposure, our findings suggest that 1.3% of neonates born in PEI during this 1-year period will have FASD. In its application to an entire provincial birth cohort, this study successfully implemented a public health-centred approach for evaluating population-based risk of FASD, with implications for practice across Canada.
BACKGROUND:Fetal alcohol spectrum disorder (FASD) is a leading preventable cause of neurodevelopmental disability in North America. The stigma associated with alcohol use and abuse during pregnancy makes it difficult to obtain information on prenatal alcohol use through self-reporting. We assessed the incidence of prenatal alcohol exposure in Prince Edward Island to facilitate future public health initiatives addressing FASD. METHODS: Prenatal alcohol exposure was examined via population-based collection of meconium and analysis of fatty acid ethyl esters (FAEEs). Fatty acid ethyl esters are nonoxidative metabolites of ethanol that are produced in the fetus. Meconium FAEE concentrations of 2.0 nmol/g or greater are indicative of frequent prenatal alcohol exposure during the last 2 trimesters of pregnancy. Samples were collected from 1307 neonates between Nov. 8, 2010, and Nov. 8, 2011, in hospitals in PEI, or from those born to mothers who resided in PEI but gave birth in Halifax, Nova Scotia. Samples were frozen and shipped for analysis. Fatty acid ethyl esters were analyzed by gas chromatography-mass spectrometry and quantified by means of deuterated internal standards. RESULTS: Of the 1307 samples collected, 1271 samples were successfully analyzed. Positive results for FAEEs were obtained in 3.1% (n = 39) of samples collected within the first 24 hours after birth. INTERPRETATION: Not all neonates exposed to heavy prenatal alcohol in utero will exhibit FASD; based on current estimates of predictive value for disease by exposure, our findings suggest that 1.3% of neonates born in PEI during this 1-year period will have FASD. In its application to an entire provincial birth cohort, this study successfully implemented a public health-centred approach for evaluating population-based risk of FASD, with implications for practice across Canada.
Authors: James F Brien; Daphne Chan; Courtney R Green; Umar Iqbal; Joey Gareri; Susan M Kobus; Brian E McLaughlin; Julia Klein; Chitra Rao; James N Reynolds; Alan D Bocking; Gideon Koren Journal: Ther Drug Monit Date: 2006-06 Impact factor: 3.681
Authors: Abdulsallam Bakdash; Pascal Burger; Tamme W Goecke; Peter A Fasching; Udo Reulbach; Stefan Bleich; Martin Hastedt; Michael Rothe; Matthias W Beckmann; Fritz Pragst; Johannes Kornhuber Journal: Anal Bioanal Chem Date: 2010-02-10 Impact factor: 4.142
Authors: Irene Zelner; Kelly Kenna; James F Brien; Alan Bocking; Richard Harding; David Walker; Gideon Koren Journal: PLoS One Date: 2013-03-22 Impact factor: 3.240
Authors: Philip A May; Amy Baete; Jaymi Russo; Amy J Elliott; Jason Blankenship; Wendy O Kalberg; David Buckley; Marita Brooks; Julie Hasken; Omar Abdul-Rahman; Margaret P Adam; Luther K Robinson; Melanie Manning; H Eugene Hoyme Journal: Pediatrics Date: 2014-11 Impact factor: 7.124
Authors: H Eugene Hoyme; Wendy O Kalberg; Amy J Elliott; Jason Blankenship; David Buckley; Anna-Susan Marais; Melanie A Manning; Luther K Robinson; Margaret P Adam; Omar Abdul-Rahman; Tamison Jewett; Claire D Coles; Christina Chambers; Kenneth L Jones; Colleen M Adnams; Prachi E Shah; Edward P Riley; Michael E Charness; Kenneth R Warren; Philip A May Journal: Pediatrics Date: 2016-07-27 Impact factor: 7.124
Authors: L L English; G Mugyenyi; I Nightingale; G Kiwanuka; J Ngonzi; B E Grunau; S MacLeod; G Koren; K Delano; J Kabakyenga; M O Wiens Journal: Matern Child Health J Date: 2016-10